A maker of medical devices for treating cardiovascular disease and cancer, AngioDynamics builds tools like the NanoKnife ablation system, the Auryon atherectomy device, and the VenaCure laser for varicose veins, used by interventional radiologists, cardiologists, and vascular surgeons. It began in 1988 as a division of E-Z-EM, a company known for imaging contrast agents, and its name blends "angio" (blood vessels) with "dynamics." Its NanoKnife system, which uses electrical pulses rather than heat to destroy prostate tumors, was named one of TIME's Best Inventions of 2025.
AngioDynamics sues Endovascular Engineering over alleged patent infringement of its thrombectomy technology
On April 23, 2026, AngioDynamics filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Endovascular Engineering, Inc. (E2).
Show detailsHide details
The complaint alleges E2's Hēlo Thrombectomy System unlawfully incorporates features covered by AngioDynamics' registered patents, including its self-expanding funnel technology.
AngioDynamics seeks damages and equitable relief in the lawsuit.
The company states that enforcing its intellectual property rights supports continued innovation and patient care.
The filing includes forward-looking statements about the litigation's outcome and associated costs.
AngioDynamics CEO James C. Clemmer to retire by Nov 30, 2026, with transition agreement
The agreement allows for continued vesting of Clemmer's equity awards until his separation of service date, with immediate vesting of stock options and service-based RSUs after that date.
Show detailsHide details
On February 3, 2026, AngioDynamics entered into a Transition and Retirement Agreement with CEO James C. Clemmer, who will serve until a successor is appointed or November 30, 2026, whichever is earlier.
On January 30, 2026, the Board approved retention agreements for the executive leadership team, excluding Clemmer, with cash awards based on base salary.
Named executive officers Trowbridge, Piccinini, Nighan, and Campbell are entitled to retention awards of 150% of base salary, while Weiss and other executive leadership team members receive 50%.
Retention awards are payable if the recipient remains employed until 6 months after a new CEO starts or June 1, 2027, whichever is earlier.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits
AngioDynamics CEO presents at J.P. Morgan 44th Annual Healthcare Conference; updates FY2026 guidance
FY2026 net sales guidance raised to $312–$314M (from $308–$313M), with Med Tech growth unchanged at +14–16% and Med Device growth raised to +0–1%.
Show detailsHide details
On January 14, 2026, CEO James Clemmer presented at the J.P. Morgan 44th Annual Healthcare Conference; slides furnished as Exhibit 99.1.
Adjusted EBITDA guidance increased to $8.0–$10.0M (from $6.0–$10.0M); adjusted EPS unchanged at ($0.33)–($0.23); free cash flow expected positive for the full year.
As of Nov 30, 2025, cash was $41.6M with zero debt; company has a revolving line of credit.
Presentation highlighted Auryon (PAD), AlphaVac (PE), and NanoKnife (prostate cancer) as key growth platforms, with combined US TAM projected to grow from $7.2B to $10.9B by FY31.
7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
AngioDynamics reports Q1 FY2026 net sales of $75.7M, up 12.2% pro forma, and raises full-year guidance.
Net sales for the fiscal first quarter ended August 31, 2025 were $75.7 million, a 12.2% increase on a pro forma basis year-over-year.
Show detailsHide details
Med Tech segment net sales grew 26.1% to $35.3 million, marking the fourth consecutive quarter of over 20% growth.
GAAP net loss was $10.9 million, or $0.26 per share; adjusted net loss was $4.2 million, or $0.10 per share.
Adjusted EBITDA was $2.2 million, compared to $(0.2) million in the prior-year quarter.
The company raised FY2026 guidance for net sales, Med Tech growth, Adjusted EBITDA, and Adjusted EPS, and expects to be cash flow positive for the full year.
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits